Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. - Wikidata - awgldk - TriplyDB

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

http://www.wikidata.org/entity/Q34474458

about

Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene Computational systems analysis of dopamine metabolism Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Vesicular monoamine transporter 2: role as a novel target for drug development Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease Experimenting with spirituality: analyzing The God Gene in a nonmajors laboratory course Identification of a gastrin response element in the vesicular monoamine transporter type 2 promoter and requirement of 20 S proteasome subunits for transcriptional activity Vesicular integrity in Parkinson's disease The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease Brain serotonergic circuitries Associations among types of impulsivity, substance use problems and neurexin-3 polymorphisms.VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.Monoamine transporters: vulnerable and vital doorkeepers.Animal models of the non-motor features of Parkinson's disease.Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression In vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective.PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals.N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease.DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.Identification of potential drugs for Parkinson's disease based on a sub-pathway method.Zingerone activates VMAT2 during MPP(+) -induced Cell Death.

P2860

Q21091188-13B0A92A-F4E1-4EBB-94EE-D0CBDC6FDD98 Q21144295-FC682095-601D-4DEE-9DBA-8C76ABBC98C1 Q24601233-D4EE3342-B4DF-4AD7-9307-79A57206C193 Q24647764-0D144015-0A5B-4C89-85EC-9D7C4189F5F3 Q27335848-BA6F5CD1-140A-4BA1-B748-D3B4B3F0FCA8 Q28271336-00DD0EBE-EF26-4B03-8A3B-CA30264408B8 Q28298413-C7CAB3C4-6C4B-4E40-9428-AA6ADBA87122 Q28385737-FC7E9A1B-C132-4B2B-8A78-75969458119B Q30430534-FD8F90A3-B164-462A-BC12-C4D93D900D9C Q33724885-6B28B43D-D44F-499D-A46D-7AA9EF4EE32E Q33854736-05AA8AF0-662A-4B17-A4D5-B84799FED5D5 Q33919434-82BE617B-5C9E-422D-A0C1-402E14E80D27 Q33919548-2AF2B707-3B29-4C8E-85D3-3CFE347062A0 Q34595165-83860B3A-9C1D-4CF4-B025-A9BDB70E6B20 Q35184890-1A894C9D-EDF4-4C0F-8E34-92195741CCAE Q35237299-953F9CDF-A102-4428-A758-11136B44BBFF Q35661896-B17F0509-B0DC-41D0-B295-3454EF7ADF08 Q35775723-467D72B3-22DF-48B6-93D5-19709F601572 Q35877150-3C91077D-D177-431B-9A0A-9FB2D07F2951 Q36235578-7DB02099-A7EC-412C-8E5A-3CE848F6F1E0 Q36585297-40D37C75-26EC-44C1-82A2-2AB28CBE9491 Q36691830-BEFC760F-F425-400D-A905-484C7312A760 Q36708352-55DB0078-7B9C-411F-AE51-EF0F34569A61 Q36724670-FC05A42A-3696-423A-B4EA-17D81E79F1FA Q36773604-2232B80C-94DD-4AE1-9119-9AFEEE987297 Q36942673-C2EBCB29-C7DB-4067-B495-A72E651466E8 Q37136467-CFD32DF8-1915-410B-B2B3-F652F16B453C Q37320854-F88D0A57-E104-459E-8528-9DE8AEC46454 Q37381249-508F1A76-D1E8-46CF-9ECD-F8671AA2BDC2 Q37589110-F7838006-5E39-4896-A734-EBB373BF72E2 Q37711589-E670EC5A-CEF0-4B3E-B498-CFD0D91DD52C Q37741285-F527AB73-DCC3-4CA0-81DE-C53D393ADAFD Q38366271-175840F1-1410-43CE-9E25-3056DE6403A6 Q38926644-90370038-A345-4CDC-8FDB-70CA6045B337 Q39154570-8EF45BEB-4B40-42C6-A303-FE73DA8F2354 Q39298707-8DE6E351-20C9-430F-9B58-5CA5DBAC8DC2 Q41031814-BD19D8C9-A5B4-458C-9A3F-75FDBD98509D Q41927560-CF7069B8-81EA-42AF-97DE-64528D95E65C Q42703601-2425D2A1-1E2D-43D5-83E7-4B1012815D17 Q46683287-C72E9080-364A-46BC-AE1A-671AE8D828E9

P2860

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

http://www.wikidata.org/entity/Q34474458

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@ast

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@en

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@nl

type

label

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@ast

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@en

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@nl

prefLabel

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@ast

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@en

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@nl

P1433

Q34474458-B1FDC976-F190-47D0-9526-07FC66580BFA

P1476

Q34474458-A293E5CA-A6F3-49D6-BC10-D1275C7DA694

P2093

Q34474458-232327A5-7A54-4BD2-B448-96756837DBE0

Q34474458-8A6EE801-9534-4B3C-B715-B14EA9AFB651

Q34474458-B0FBF498-0927-4D1A-A547-B7604E6B6CFA

Q34474458-D516D449-2BFE-496C-829C-6C70D3C9CA05

P2860

Q34474458-16FE7593-8F6B-478D-9E54-A19C2EB7438A

Q34474458-19EB562B-5EC3-4720-9FAD-3F5F92154957

Q34474458-1BF499FE-2ED1-41CB-BE2A-D05B99BE027F

Q34474458-224E5AB8-2D82-4717-93DE-E257E61354D3

Q34474458-2358FC13-B04C-492A-81F6-6A65E56A2FA7

Q34474458-26D8DF0E-59A9-421C-8E6E-8C3331123AC1

Q34474458-2F96A995-9322-4316-89DC-6D4769F4DFB6

Q34474458-3A480644-3014-4860-80F7-2D807AA9DE89

Q34474458-3AB5E943-37B8-4694-B62E-34761664E543

Q34474458-3BA5B1BC-C512-4EFA-8AA2-97F67A8BF9E6

P304

Q34474458-EBFDE9E2-0591-4D19-8188-85555C78398E

P31

Q34474458-B70D5403-564D-4849-A1BF-648A19F1078E

P356

Q34474458-1C23D7E9-E0BC-441F-B869-034FD16C3DC9

P433

Q34474458-7D1D63B2-2454-4E95-80BB-CC5E8AAE7893

P478

Q34474458-0B43A119-3490-478F-8841-096B2B5E710C

P50

Q34474458-4BE46785-47F6-41A4-9CA9-370BDC9F85E7

P577

Q34474458-8297A4C8-099F-4428-859B-DD9063A166D1

P5875

Q34474458-A04C3619-89FA-433F-9AFC-2EFEAAE52BE7

P698

Q34474458-06882B2E-4DAE-4AC4-8498-8BBCA64D2A8E

P921

Q34474458-AE74F1EB-167B-4667-A576-D1A09A036875

P932

Q34474458-8A08F3B9-2168-441F-8024-1CAF64CAC7CE

P356

P1433

Human Molecular Genetics

P1476

Gain-of-function haplotypes in ...... or Parkinson disease in women.

@en

P2093

Andres Ruiz-Linares

http://www.w3.org/2001/XMLSchema#string

Angelika D Wahner

http://www.w3.org/2001/XMLSchema#string

Charles E Glatt

http://www.w3.org/2001/XMLSchema#string

Daniel J White

http://www.w3.org/2001/XMLSchema#string

P2860

A New Statistical Method for Haplotype Reconstruction from Population Data

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

Are men at greater risk for Parkinson's disease than women?

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.

What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system.

The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins.

P304

299-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDI445

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7430978

http://www.w3.org/2001/XMLSchema#string

P698

16339215

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3643966

http://www.w3.org/2001/XMLSchema#string